Colorectal adenoma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients must meet all 6 of the following criteria to be eligible for this study: 1) Aged 18–75 years; gender is not restricted. 2) Patients diagnosed via colonoscopy within the past 6 months and who have undergone complete endoscopic resection of pathologically confirmed advanced colorectal adenomas (including villous adenomas, tubular-villous adenomas, and tubular adenomas). Patients must have histologically confirmed presence of 1–6 colorectal adenomas. 3) With or without symptoms such as constipation, diarrhea, or abdominal distension. 4) Boston Bowel Preparation Score = 6. 5) Familial adenomatous polyposis or polyposis has been ruled out based on medical and family history. 6) Willing to participate and has signed an informed consent form.
Exclusion criteria
Exclusion criteria: Patients meeting any one or more of the following criteria should be excluded: 1) Patients with adenomas that were not completely resected during a previous colonoscopy; 2) Patients with polyps that have already undergone malignant transformation, or those with familial adenomatous polyposis; 3) Patients on long-term therapy with aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2) inhibitors, vitamin D, or calcium supplements, or those undergoing long-term systemic immunotherapy; 4) Patients unable to tolerate colonoscopy; 5) Patients with inadequate bowel preparation for colonoscopy or whose examination duration was less than 6 minutes; 6) Patients with acute or chronic conditions that may significantly affect treatment and prognosis, such as severe cardiovascular or cerebrovascular disease, severe liver or kidney disease, or serious postoperative complications; 7) Pregnant women, women planning to become pregnant, or breastfeeding women; 8) Patients with allergies or contraindications to the relevant medications; 9) Patients with underlying psychiatric disorders that prevent them from cooperating fully with the trial; 10) Patients with concurrent malignant tumors; 11) Patients currently participating in other clinical trials within the past month; 12) Other circumstances deemed unsuitable for inclusion by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adenoma recurrence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement Rate of Traditional Chinese Medicine Syndromes;Anxiety;Depression;Number and nature of intestinal polyps; | — |
Countries
China
Contacts
Wangjing Hospital, China Academy of Chinese Medical Sciences